WO1999009967A3 - Therapie hypocholesterolemiante - Google Patents
Therapie hypocholesterolemiante Download PDFInfo
- Publication number
- WO1999009967A3 WO1999009967A3 PCT/US1998/017459 US9817459W WO9909967A3 WO 1999009967 A3 WO1999009967 A3 WO 1999009967A3 US 9817459 W US9817459 W US 9817459W WO 9909967 A3 WO9909967 A3 WO 9909967A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cholesterol level
- average
- density lipoprotein
- cholesterol
- lipoprotein cholesterol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98943329A EP1007019A2 (fr) | 1997-08-26 | 1998-08-21 | Therapie hypocholesterolemiante |
CA002300165A CA2300165A1 (fr) | 1997-08-26 | 1998-08-21 | Therapie hypocholesterolemiante |
AU91153/98A AU9115398A (en) | 1997-08-26 | 1998-08-21 | Cholesterol-lowering therapy |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5696697P | 1997-08-26 | 1997-08-26 | |
US60/056,966 | 1997-08-26 | ||
US7685998P | 1998-03-05 | 1998-03-05 | |
US60/076,859 | 1998-03-05 | ||
US8536098P | 1998-05-13 | 1998-05-13 | |
US60/085,360 | 1998-05-13 | ||
GBGB9814415.7A GB9814415D0 (en) | 1998-07-03 | 1998-07-03 | Cholesterol-lowering therapy |
GB9814415.7 | 1998-07-03 | ||
GBGB9815851.2A GB9815851D0 (en) | 1998-07-21 | 1998-07-21 | Cholesterol-lowering therapy |
GB9815851.2 | 1998-07-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1999009967A2 WO1999009967A2 (fr) | 1999-03-04 |
WO1999009967A3 true WO1999009967A3 (fr) | 1999-05-20 |
WO1999009967B1 WO1999009967B1 (fr) | 1999-07-08 |
Family
ID=27517467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/017459 WO1999009967A2 (fr) | 1997-08-26 | 1998-08-21 | Therapie hypocholesterolemiante |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1007019A2 (fr) |
AU (1) | AU9115398A (fr) |
CA (1) | CA2300165A1 (fr) |
WO (1) | WO1999009967A2 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0461548A2 (fr) * | 1990-06-11 | 1991-12-18 | E.R. SQUIBB & SONS, INC. | Procédé pour empêcher une deuxième crise cardiaque utilisant un inhibiteur de l'enzyme HMG-CoA |
EP0528515A2 (fr) * | 1991-06-04 | 1993-02-24 | Merck & Co. Inc. | Inhibiteurs de réductase de HMG-CoA dans la prévention de la resténose après angioplastic coronaire |
EP0671171A1 (fr) * | 1994-01-18 | 1995-09-13 | Bristol-Myers Squibb Company | Utilisation d'inhibiteurs de la HMG CoA, réductase dans la fabrication d'un médicament pour réduire ou prevenir les risques d'attaques cardiaques |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
-
1998
- 1998-08-21 WO PCT/US1998/017459 patent/WO1999009967A2/fr not_active Application Discontinuation
- 1998-08-21 AU AU91153/98A patent/AU9115398A/en not_active Abandoned
- 1998-08-21 CA CA002300165A patent/CA2300165A1/fr not_active Abandoned
- 1998-08-21 EP EP98943329A patent/EP1007019A2/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0461548A2 (fr) * | 1990-06-11 | 1991-12-18 | E.R. SQUIBB & SONS, INC. | Procédé pour empêcher une deuxième crise cardiaque utilisant un inhibiteur de l'enzyme HMG-CoA |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
EP0528515A2 (fr) * | 1991-06-04 | 1993-02-24 | Merck & Co. Inc. | Inhibiteurs de réductase de HMG-CoA dans la prévention de la resténose après angioplastic coronaire |
EP0671171A1 (fr) * | 1994-01-18 | 1995-09-13 | Bristol-Myers Squibb Company | Utilisation d'inhibiteurs de la HMG CoA, réductase dans la fabrication d'un médicament pour réduire ou prevenir les risques d'attaques cardiaques |
Non-Patent Citations (9)
Title |
---|
HARIA M. ET AL: "Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.", DRUGS, (1997) 53/2 (299-336). REFS: 267 ISSN: 0012-6667 CODEN: DRUGAY, New Zealand, XP002095845 * |
KELLICK K A ET AL: "Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.", AMERICAN JOURNAL OF CARDIOLOGY, (1995 JUL 13) 76 (2) 62A-64A. JOURNAL CODE: 3DQ. ISSN: 0002-9149., United States, XP002095843 * |
MARCUS A.: "Role of the HMG-CoA reductase inhibitors in the treatment of dyslipidemia An evolutionary review.", CARDIOVASCULAR REVIEWS AND REPORTS, (1996) 17/1 (10-11+15-16+21-24+26-27) ISSN: 0197-3118 CODEN: CRRPD4, United States, XP002095841 * |
MEISER, B. M. ET AL: "Simvastatin decreases accelerated graft vessel disease (GVD) after heart transplantation in an animal model", TRANSPLANT. PROC. (1993), 25(2), 2077-9 CODEN: TRPPA8;ISSN: 0041-1345, XP002095842 * |
MOTOMURA N. ET AL: "HMG-CoA reductase inhibitors in organ transplantation.", JOURNAL OF NEPHROLOGY, (1997) 10/2 (68-76). REFS: 127 ISSN: 1121-8428 CODEN: JLNEEL, Italy, XP002095844 * |
PFEIFER M.A. ET AL: "Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients.", AMERICAN JOURNAL OF CARDIOLOGY, (1995) 76/9 (98C-106C). ISSN: 0002-9149 CODEN: AJCDAG, United States, XP000579209 * |
PROBSTFIELD, JEFFREY L. (1) ET AL: "Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study.", AMERICAN JOURNAL OF CARDIOLOGY, (1995) VOL. 76, NO. 9, PP. 47C-53C. ISSN: 0002-9149., XP002095840 * |
SOUTHWORTH M R ET AL: "The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.", ANNALS OF PHARMACOTHERAPY, (1997 APR) 31 (4) 489-91. REF: 32 JOURNAL CODE: BBX. ISSN: 1060-0280., United States, XP002095847 * |
STEIN E. ET AL: "Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesterolemia.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, (1997) 2/1 (7-16). REFS: 30 ISSN: 1074-2484 CODEN: JCPTFE, United States, XP002095846 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999009967B1 (fr) | 1999-07-08 |
CA2300165A1 (fr) | 1999-03-04 |
AU9115398A (en) | 1999-03-16 |
WO1999009967A2 (fr) | 1999-03-04 |
EP1007019A2 (fr) | 2000-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Eisenberg | Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials | |
AU5074196A (en) | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor | |
BR0013704A (pt) | Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares | |
PL307463A1 (en) | Pharmaceutical agent especially for inhibiting osteoporosis and lowering cholesterol level in blood serum | |
ZA957088B (en) | A system for the tracking and management of transactions in a pit area of a gaming establishment. | |
CA2152351A1 (fr) | Combinaison d'un inhibiteur de la biosynthese du cholesterol et d'un inhibiteur de l'absorption de cholesterol .beta.-lactamique | |
AU5691198A (en) | Nonwoven web laminate having relatively hydrophilic zone and related method for its manufacture | |
WO1999066031A3 (fr) | Preparation pharmaceutique a base d'un facteur vii | |
WO2000054759A3 (fr) | Modulateurs du lxr | |
CA2268439A1 (fr) | Extrait d'ecorce de citrus utilise en tant qu'inhibiteur de 3-hydroxy-3-methyl-glutaryl coenzyme a (hmg coa) reductase | |
WO2001015676A3 (fr) | Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides | |
WO1998051289A3 (fr) | Monoesters de probucol destines au traitement de troubles cardio-vasculaires et inflammatoires | |
EP0713706A3 (fr) | Agent abaissant le lipoprotéine (a), agent abaissant le cholestérol et médicaments contenant ces agents | |
AU2003291206A1 (en) | Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease | |
WO2000033790A3 (fr) | Procedes et compositions pour prevention et traitement de liaisons arterielles a l'aide de medicaments anti-inflammatoires non steroidiens | |
WO2001041754A8 (fr) | Inhibiteurs d'agregation plaquettaire induite par le collagene | |
AU5544994A (en) | Use of 17alpha-dihydroequilenin for lowering cholesterol | |
WO1999009967A3 (fr) | Therapie hypocholesterolemiante | |
Smith Jr | Review of recent clinical trials of lipid lowering in coronary artery disease | |
EP0989852A4 (fr) | Methode de traitement de l'atherosclerose a l'aide d'un inhibiteur de mpt et de medicaments reduisant le cholesterol | |
WO2002072104A3 (fr) | Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol | |
NZ505637A (en) | E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol and pharmaceutical compositions useful in lowering serum cholesterol | |
WO2002007753A3 (fr) | Procede de traitement d'une angine de poitrine instable | |
WO2000069445A8 (fr) | Polytherapie pour traiter l'hypercholesterolemie | |
Otterstad et al. | The HOPE study: comparison with other trials of secondary prevention. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2300165 Country of ref document: CA Ref country code: CA Ref document number: 2300165 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998943329 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 91153/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1998943329 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998943329 Country of ref document: EP |